All posts

OpenText wins target raise from Eight Capital

Eight Capital analyst Adhir Kadve likes the look of Canadian enterprise information management software company OpenText (OpenText Stock Quote, Charts, News, Analysts, Financials NASDAQ:OTEX), reiterating a “Buy” rating in a Friday note to clients while raising his 12-month target from $45 to $50 per share. Kadve said the early results look good on OTEX’s integration efforts with last year’s big acquisition MicroFocus, while the company’s latest quarterly numbers were a beat of estimates.

OpenText released its fiscal third quarter 2023 financials on Thursday, coming in with revenue up 41 per cent year-over-year to $1.24 billion, beating the consensus estimate at $1.18 billion as well as Kadve’s call at $1.17 billion. Annual recurring revenue at $1.01 billion made up 81 per cent of the Q3 topline. (All figures in US dollars.)

On adjusted EBITDA, OTEX hit $365 million for a 29 per cent margin, also coming in ahead of the Street’s estimate at $306 million and Kadve’s forecast at $300 million.

OpenText’s share price dropped sharply last year after the company announced the major acquisition of MicroFocus, with critics seemingly unhappy, among others, with the latter’s recent lack of revenue momentum. 

But so far so good, according to Kadve, who noted MicroFocus’ contribution to OTEX’s Q3 was $374 million in revenue, which was ahead of management’s previous expectations of $310-$325 million. Management also said it was well ahead of schedule on its planned operational integration.

“We continue to believe that, OpenText’s track record of successful acquisitions should not be ignored, which gives us confidence in the company’s ability to successfully integrate Micro Focus, and this quarter only serves as an early validation of that thesis. As the company continues to execute, we see shares returning to historical levels (11x adj. EBITDA),” Kadve said.

The analyst adjusted his estimates on OpenText and is now calling for full 2023 revenue and EBITDA of $4,499 million and $1,489 million, respectively, and full 2024 revenue and EBITDA of $6,125 million and $2,330 million, respectively.

“A large part of the increase in outlook stems from the strength coming from Micro Focus and key measures taken by management to improve renewal rates at the asset,” he said.

“To that end, management noted that they will continue to make steady progress towards improving renewal rates at Micro Focus from the low 80 per cent at acquisition to mid-80 per cent by the end of F23 and reiterated their goal to reach OpenText level renewals at Micro Focus (i.e.mid-90 per cent). The pipeline of new deals from MF was strong with Business Network and Content Services called out as areas seeing particular strength,” Kadve said.

At the time of publication, Kadve’s new $50 target represented a projected one-year return of 37 per cent.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: otex
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Should you buy AMZN? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on Amazon (Amazon Stock… [Read More]

9 hours ago

These cannabis stocks will benefit most from reclassification

It happened. The move that everyone in the cannabis sector was hoping for came about swiftly on the last day… [Read More]

15 hours ago

Is AMD stock a buy? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Suji Desilva has maintained his "Buy" rating on Advanced Micro Devices… [Read More]

16 hours ago

Is Wolfspeed stock still a buy?

Ahead of the company's third quarter results, Roth MKM analyst Scott Irwin has maintained his "Buy" rating on Wolfspeed (Wolfspeed… [Read More]

17 hours ago

WELL Health inks five-year deal with Microsoft

It's become one of the biggest players in the Canadian healthcare space, now WELL Health (WELL Health Stock Quote, Chart,… [Read More]

2 days ago

Is Thomson Reuters stock a buy right now?

Its stock has made a since last October, but is there more upside left in Thomson Reuters (Thomson Reuters Stock… [Read More]

2 days ago